Summary
The accurate diagnosis of retinoblastoma does not only save the lives of our young patients, but sometimes makes preservation of the treated globes possible with a visual function enabling our patients to live a nearly normal life. In this article the measures for an early diagnosis are described in detail. Delayed diagnosis because of neglecting early signs of a retinoblastoma like leucocoria as diagnosed by the Brückner Test or seen on a photograph as well as strabism will lead to loss of one or both eyes, sometimes threatening the lives of our young patients. The following article deals with the unsolved problem of delayed diagnosis and summarizes the key facts about retinoblastoma addressing those who will see this life-and globe threatening disease first. A short summary of the Retinoblastoma study RBA 2003 is given which was developed at the Department of Paediatric Haematology/Oncology in collaboration with the Department of Ophthalmology.
Zusammenfassung
Die rechtzeitige Diagnose eines Retinoblastoms rettet nicht nur das Leben des Kindes, sondern hat einen entscheidenden Beitrag für den Erhalt eines oder sogar beider Augen mit einem z.T. erstaunlich gutem Sehvermögen. In dieser Arbeit wird im Detail auf jene Maßnahmen eingegangen, die zu einer rechtzeitigen Diagnose des Retinoblastoms führen. Werden die wichtigen Erstsymptome wie Leukokorie oder Schielen als Erstsymptom eines Retinoblastoms negiert, droht der Verlust eines oder beider Augen. Neben der nicht gelösten Problematik der Früherkennung eines Retinoblastoms wird in der folgenden Arbeit auch auf die Inzidenz, die klinischen Zeichen, die Vererblichkeit und die Therapiemodalitäten eingegangen. Die an der Medizinischen Universität Graz entwickelte Therapie-Optimierungsstudie RBA 2003 wird kurz dargestellt.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
Literatur
Abramson DH, Frank CM (1998) Second nonocular tumors in survivors of bilateral retinoblastoma: a possible age effect on radiation-related risk. Ophthalmology 105: 573–579 (Discussion 579–580)
Bechrakis NE, Bornfeld N, Schueler A, Coupland SE, Henze G, Foerster MH (1998) Clinicopathologic features of retinoblastoma after primary chemoreduction. Arch Ophthalmol 116: 887–893
Bornfeld N, Schueler A, Bechrakis N, Henze G, Havers W (1997) Preliminary results of primary chemotherapy in retinoblastoma. Klin Pädiatr 209: 216–221
Eng C, Li FP, Abramson DH, Ellsworth RM, Wong FL, Goldman MB, et al (1993) Mortality from second tumors among long-term survivors of retinoblastoma. J Nat Cancer Inst 85: 1121–1128
Freigassner P, Langmann G, Kerbl R, Urban Ch (2001) Retinoblastomtherapie an der Univ.-Augenklinik Graz. Spektrum Augenheilkd 15: 154–158
Gombos DS, Kelly A, Coen PG, Kingston J, Hungerford JL (2002) Retinoblastoma treated with primary chemotherapy alone: the significance of tumor size, location and age. Br J Ophthalmol 86: 80–83
Hopping W (1983) The new Essen prognosis classification for conservative sight-saving treatment of retinoblastoma. In: Lommatzsch PK, Blodi FC (eds) Intraocular tumors: International Symposium under the auspices of the European ophthalmological society. Springer, Berlin, pp 497–505
Imhof SM, Mourits M, Hofmann P, Zonneveld FW, Schipper J, Moll AC, et al (1996) Quantification of orbital and mid-facial growth retardation after megavoltage external beam irradiation in children with retinoblastoma. Ophthalmology 103: 263–268
Kleinerman RA, Tucker MA, Tarone RE, Abramson DH, Seddon JM, Stovall M, et al (2005) Risk of new cancers in long-term survivors of retinoblastoma: an extended follow-up. J Clin Oncol 23: 2272–2279
Kupfer C (1953) Retinoblastoma treated with intravenous nitrogen mustard. Am J Ophthalmol 53: 505
Knudson AG Jr (1971) Mutation and cancer: statistical study of retinoblastoma. Proc Natl Acad Sci U S A 68: 820–823
Langmann G, Langmann A, Sovinz P, Urban Ch (2004) Vorschlag einer Vereinheitlichung der Retinoblastomtherapie in Österreich. Spektrum Augenheilkd 18: 34–39
Lohmann DR (1999) RB1 gene mutations in retinoblastoma. Hum Mutat 14: 283–288
Murphree L (2005) Intraocular retinoblastoma: the case for a new group classification. Ophthalmol Clin North Am 18: 41–53
Reese AB, Ellsworth RM (1964) Management of retinoblastoma. Ann NY Acad Sci 114: 958–962
Shields CL, Honavar SG, Meadows AT, Shields JA, Demirci H, Singh A, et al (2002) Chemoreduction plus focal therapy for retinoblastoma: factors predictive of need for treatment with external beam radiotherapy or enucleation. Am J Ophthalmol 133: 657–664
Shields CL, Shelil A, Cater J, Meadows AT, Shields JA (2003) Development of new retinoblastomas after 6 cycles of chemoreduction for retinoblastoma in 162 eyes of 106 consecutive patients. Arch Ophthalmol 121: 1571–1576
Shields CL, Meadows AT, Leahey AM, Shields JL (2004) Continuing challenges in the management of retinoblastoma with chemotherapy. Retina 24: 849–862
Shields CL, Shields JA, Cater J, Othmane I, Singh AD, Micaily B (2001) Plaque radiotherapy for retinoblastoma: long-term tumor control and treatment complications in 208 tumors. Ophthalmology 108: 2116–2121
Schueler AO, Jurklies C, Heimann H, Wieland R, Havers W, Bornfeld N (2003) Thermochemotherapy in hereditary retinoblastoma. Br J Ophthalmol 87: 90–95
Stallard HB (1952) Irradiation of retinoblastoma (glioma retinae). Lancet 1: 1046–1049
Sovinz P, Urban C, Lackner H, Benesch M, Langmann G (2006) Retinoblastoma: a proposal for a multimodal treatment concept for intraocular retinoblastoma in Austria Wien Klin Wochenschr 118 (1–2): P22–30
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Langmann, G., Wackernagel, W., Mayer, C. et al. Retinoblastom: späte Diagnose auch in Österreich. Spektrum Augenheilkd. 24, 2–5 (2010). https://doi.org/10.1007/s00717-010-0382-1
Issue Date:
DOI: https://doi.org/10.1007/s00717-010-0382-1